Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF 9.86
(2.49%)
CHF 9.86
(2.49%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 54.78 Million CHF | 177.08% |
| 2022 | -71.07 Million CHF | -28.0% |
| 2021 | -55.52 Million CHF | 17.93% |
| 2020 | -67.65 Million CHF | -256.61% |
| 2019 | -18.97 Million CHF | 64.99% |
| 2018 | -54.18 Million CHF | -5.15% |
| 2017 | -51.53 Million CHF | -45.51% |
| 2016 | -35.41 Million CHF | -695.31% |
| 2015 | 5.94 Million CHF | 178.96% |
| 2014 | -7.53 Million CHF | -30.91% |
| 2013 | -5.75 Million CHF | 81.7% |
| 2012 | -31.44 Million CHF | -12.97% |
| 2011 | -27.83 Million CHF | -147.32% |
| 2010 | -11.25 Million CHF | -143.42% |
| 2009 | 25.92 Million CHF | 158.05% |
| 2008 | -44.65 Million CHF | -60.22% |
| 2007 | -27.87 Million CHF | 1.37% |
| 2006 | -28.25 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -7.63 Million CHF | 0.0% |
| 2024 Q1 | -7.63 Million CHF | -109.77% |
| 2023 Q2 | -23.33 Million CHF | -100.0% |
| 2023 Q3 | 39.05 Million CHF | 267.38% |
| 2023 Q4 | 78.11 Million CHF | 100.0% |
| 2023 Q1 | -11.66 Million CHF | 71.78% |
| 2023 FY | 54.78 Million CHF | 177.08% |
| 2022 Q4 | -41.35 Million CHF | -100.0% |
| 2022 Q3 | -20.67 Million CHF | 30.44% |
| 2022 Q2 | -29.72 Million CHF | -100.0% |
| 2022 Q1 | -14.86 Million CHF | 57.55% |
| 2022 FY | -71.07 Million CHF | -28.0% |
| 2021 FY | -55.52 Million CHF | 17.93% |
| 2021 Q4 | -35 Million CHF | -100.0% |
| 2021 Q1 | -10.25 Million CHF | 71.37% |
| 2021 Q2 | -20.51 Million CHF | -100.0% |
| 2021 Q3 | -17.5 Million CHF | 14.7% |
| 2020 Q1 | -15.91 Million CHF | -300.75% |
| 2020 Q2 | -31.82 Million CHF | -100.0% |
| 2020 Q3 | -17.91 Million CHF | 43.71% |
| 2020 FY | -67.65 Million CHF | -256.61% |
| 2020 Q4 | -35.83 Million CHF | -100.0% |
| 2019 Q3 | 3.96 Million CHF | 114.73% |
| 2019 FY | -18.97 Million CHF | 64.99% |
| 2019 Q2 | -26.9 Million CHF | -100.0% |
| 2019 Q1 | -13.45 Million CHF | 5.7% |
| 2019 Q4 | 7.92 Million CHF | 100.0% |
| 2018 Q4 | -14.26 Million CHF | -13.45% |
| 2018 FY | -54.18 Million CHF | -5.15% |
| 2018 Q3 | -12.57 Million CHF | 8.07% |
| 2018 Q2 | -13.67 Million CHF | 0.0% |
| 2018 Q1 | -13.67 Million CHF | 24.86% |
| 2017 Q2 | -11.35 Million CHF | 0.0% |
| 2017 FY | -51.53 Million CHF | -45.51% |
| 2017 Q4 | -18.19 Million CHF | -71.35% |
| 2017 Q3 | -10.62 Million CHF | 6.47% |
| 2017 Q1 | -11.35 Million CHF | -30.2% |
| 2016 FY | -35.41 Million CHF | -695.31% |
| 2016 Q4 | -8.72 Million CHF | 0.0% |
| 2016 Q3 | -8.72 Million CHF | 2.93% |
| 2016 Q2 | -8.98 Million CHF | 0.0% |
| 2016 Q1 | -8.98 Million CHF | -245.76% |
| 2015 Q4 | 6.16 Million CHF | 0.0% |
| 2015 Q2 | -3.19 Million CHF | 0.0% |
| 2015 FY | 5.94 Million CHF | 178.96% |
| 2015 Q1 | -3.19 Million CHF | -31.33% |
| 2015 Q3 | 6.16 Million CHF | 293.24% |
| 2014 Q1 | -1.54 Million CHF | -22.34% |
| 2014 FY | -7.53 Million CHF | -30.91% |
| 2014 Q4 | -2.42 Million CHF | 0.0% |
| 2014 Q3 | -2.42 Million CHF | -57.01% |
| 2014 Q2 | -1.54 Million CHF | 0.0% |
| 2013 Q2 | -1.61 Million CHF | 0.0% |
| 2013 Q1 | -1.61 Million CHF | 87.58% |
| 2013 FY | -5.75 Million CHF | 81.7% |
| 2013 Q4 | -1.26 Million CHF | 0.0% |
| 2013 Q3 | -1.26 Million CHF | 21.61% |
| 2012 Q3 | -12.98 Million CHF | 0.0% |
| 2012 FY | -31.44 Million CHF | -12.97% |
| 2012 Q4 | -12.98 Million CHF | 0.0% |
| 2011 FY | -27.83 Million CHF | -147.32% |
| 2010 FY | -11.25 Million CHF | -143.42% |
| 2009 FY | 25.92 Million CHF | 158.05% |
| 2008 FY | -44.65 Million CHF | -60.22% |
| 2007 FY | -27.87 Million CHF | 1.37% |
| 2006 FY | -28.25 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.55 Million CHF | 618.954% |
| BB Biotech AG | -206.6 Million CHF | 126.515% |
| Basilea Pharmaceutica AG | 10.45 Million CHF | -424.18% |
| Evolva Holding SA | -105.22 Million CHF | 152.06% |
| Idorsia Ltd | -297.92 Million CHF | 118.388% |
| Kuros Biosciences AG | -13.72 Million CHF | 499.082% |
| Molecular Partners AG | -61.98 Million CHF | 188.381% |
| Relief Therapeutics Holding AG | -98.18 Million CHF | 155.797% |